If your tirzepatide stalled with PCOS and the only answer from your prescriber was a higher dose, the question you were left holding is the right one. Why did it stop working?
GoodLife Health looks for the reason before raising the dose. A clinician reads fasting insulin and thyroid together in a panel drawn every quarter. One clinician stays with you across those quarters and holds the whole picture.
Dana, whose first three months follow, is a composite patient drawn for this piece. No real patient's record is described. Her months with us show what a clinician would check and why. They also answer the first thing she asked us, which was whether she would see the same clinician each time.
- A plateau is a question to answer before it is a reason to raise the dose.
- Fasting insulin and TSH With Reflex To Free T4 are read together in every quarterly panel.
- One clinician stays with you and holds the whole picture across quarters.
- Between visits, messages go to the care team, with no response time promised.
- $299 a month. The $598 hold is released if you are not accepted and is non-refundable once charged on acceptance.
- Medication goes to the pharmacy you choose at its own price. GoodLife Health takes nothing on it.
Months of check-in forms and a dose that kept climbing
Dana has known she has PCOS for years. Her cycles have never kept a schedule. Meals leave her flat by midafternoon. One clinician offered her the pill to regulate the bleeding. Another told her to eat fewer carbohydrates. Neither one drew her fasting insulin.
Last year, she started tirzepatide through a telehealth service that prescribed it from an online questionnaire. The early months went the way she had hoped. The scale moved, her appetite quieted and her clothes fit differently. Then the loss slowed. A few weeks later, it stopped.
What happened next is the part she describes most carefully. She reported on the monthly check-in form that her weight had not changed. Within days, an email confirmed her next dose. She wrote back to ask why the medication had stopped working. The reply said that plateaus happen and that the higher dose should help. It was signed by a name she had not seen before. The next reply came from someone else again.
The nausea returned with each increase. Nobody asked about it unless she raised it herself. When she did, she received a list of foods to avoid and a reminder to drink water.
None of the people who answered her were careless in any obvious way. Each one did what the system in front of them allowed. That system had one lever. When the only tool is the dose, every plateau looks like a reason to raise it.
Dana is not looking for a miracle. She wants to know whether her body is doing something a higher dose cannot fix. She also wants one person who knows her history well enough to tell her. That is why her first question to us was about people.
If this sounds like your own last few months, asking why is reasonable. A plateau is information. Someone should read it.
Why a higher dose answers only one question
A dose increase tests one idea, which is that more of the same medication will move the number. Sometimes that is the right test. It is a poor first test when nobody has looked at what else might be going on.
A plateau can have more than one cause. The dose is only one candidate. Some of the others come out in conversation. Some show up only in blood work.
For a woman with PCOS, two measurements belong near the start of that reading. The first is fasting insulin. The second is thyroid function, which GoodLife Health draws as TSH With Reflex To Free T4. Dana had neither on record. Her last blood work was a basic panel from an annual visit. The word written beside it was normal.
Fasting insulin is measured because it can show a change before glucose turns abnormal. It is read beside the Hemoglobin A1c (HbA1c) in every quarterly panel.
Normal is a population range. A single reading shows where one morning fell inside it. It does not show which way you are moving. It says nothing at all about a marker that was never drawn.
Then there is the history. A clinician reading a plateau wants to know how long Dana spent at each dose and what her appetite did at each step. The clinician will also ask what else Dana takes, how she has been sleeping and whether the nausea has changed what she eats. Changes in her cycles, her work or her stress since the loss stopped belong in the same conversation.
None of these questions is exotic. They are hard to ask on a form. They are harder to answer well when a different person reads each reply.
That is why the same clinician matters here. A plateau is read from the line the numbers draw over months. The line exists only if one clinician and one record keep it. When each message is answered by a new name, every reply starts from the form in front of it. The obvious move from a form is the next dose.
If it stopped working, someone should find out why before the dose goes up.
GoodLife Health is built in the opposite order: diagnosis first, then treatment, then the long haul. It sells neither the drug nor the dose. The fee is the same whatever medication is indicated and whatever the dose, so a higher dose earns us nothing. The panel is therefore the first place we look.
We want to be plain about what we do not know. Dana's first panel may explain her plateau. It may show nothing that does. Either result is a better basis for the next decision than a check-in form.
Dana's first three months with one clinician
Those months, in order, looked like this. The details are the composite's. Your own would differ.
Before the first visit: the check, the intake and the review
Dana started with the eligibility check. Then came the intake, where she listed her PCOS history, every tirzepatide dose she had taken and the side effects that came with each one. She named her current prescriber and the pharmacy she uses.
At checkout, $598 was held on her card to cover the first two months. It was a hold and not a charge. If the clinician had not been able to accept her into care, the hold would have been released and she would never have been charged. Once she was accepted, the first two months were charged and became non-refundable.
Not everyone is accepted. A clinician reviewed Dana's intake before anything was charged.
Month 1: the first panel and the first visit
Dana's first panel was drawn at a lab near her home. It covered Fasting Insulin, Hemoglobin A1c (HbA1c), TSH With Reflex To Free T4, Lipid Panel, Standard, Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP, CBC (Includes Differential And Platelets) and Comprehensive Metabolic Panel. Every result went into her hands, so she could read each number and bring her own questions to the visit.
The rest of the panel is there because weight is one part of the picture. ApoB, Lp(a) and hs-CRP speak to cardiovascular risk. The clinician reads them beside the metabolic markers.
Her first video visit was with her clinician, the one she would see each quarter after. Like any direct primary care visit done well, it started from the data. They read the panel together, marker by marker. We will not invent Dana's numbers, because a real panel belongs to the person it was drawn from. What matters is the order of the conversation. The markers came first. The dose came after them.
GoodLife Health prescribes branded, FDA-approved medication only, which for tirzepatide means Zepbound or Mounjaro where indicated. If Dana's current tirzepatide had come from a compounding pharmacy, it would not be continued here. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss. In that case, the clinician reviews the current dose and decides with Dana what comes next.
Whatever the starting point, the decision belongs to the clinician and Dana together. It might be to hold the dose, to change it or to move to a different branded medication where one is indicated. Raising the dose remains possible. The difference is that the decision now follows the panel.
When medication is indicated, it is prescribed to the pharmacy Dana chooses at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on that medication. For context, LillyDirect published self-pay prices for Zepbound vials of $299 to $449 a month, depending on dose, in September 2026. Whether insurance covers a medication is between Dana, her plan and her pharmacy. Prior authorization is the pharmacy's process. We do not claim to run it, speed it or win it.
Month 2: questions between visits
The weeks between visits were where Dana's old care fell apart, so they are worth describing plainly.
In the second month, Dana's nausea flared again. She wrote to the care team the same afternoon. She did not wait for a check-in form or a scheduled renewal.
Messages go to the care team between visits. We do not promise a response time. We also do not promise that the same person types every reply. What we can describe is the structure. Dana's clinician holds her plan and her record. Every message she sends sits in that record.
That is the practical answer to her first question. The membership is built so that she sees the same clinician at each video visit and each quarterly reading. Between visits, she writes to the care team. Her record and her clinician's plan sit behind every message.
Month 3: the second panel
The second panel was drawn about 90 days after the first. It was the first time anyone had drawn a line through Dana's markers. The same clinician read it against the first panel and against everything Dana had reported in between.
One panel is a snapshot. Two panels from the same person, read by the same clinician, begin to show direction.
The next decision came from that reading. It might confirm the plan, adjust it or point to something the first panel only hinted at. We cannot tell you which. We make no promise about how much weight Dana loses after it. A promise like that would be a guess.
From month three, the membership is month to month. Dana can stay for the long haul or leave.
What it costs and what it does not do
The membership is $299 a month. At sign-up, $598 is held on the card for the first two months and charged only once a clinician accepts the patient. If the clinician cannot accept the patient, the hold is released and the patient is never charged. Once the patient is accepted, those two months are non-refundable. After them, the membership is month to month. Over a year, it comes to $3,588.
The fee covers clinicians licensed in all fifty states, four cardiometabolic lab panels a year with every result in the patient's hands, messaging with the care team and video visits. It is the same fee whatever medication is indicated and whatever the dose. Medication is separate. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The full scope is set out in what a direct primary care membership includes.
The membership pairs with insurance for catastrophic coverage. It does not replace insurance. It makes no promise that a medication will be covered or that weight loss will follow. It does not prescribe compounded GLP-1. The quarterly panel does not include the androgens. It does not answer every question PCOS raises.


What to do this week, whether or not you join
Three things are worth doing before your next dose arrives.
- Write down every dose you have taken, the date each one started and what changed in your appetite and side effects.
- Ask your current prescriber when your fasting insulin, A1C and thyroid were last drawn. Ask for the results in writing.
- Ask who reads your results and whether you will hear from the same person next month.
If your prescriber can draw those markers, read them with you and stay, you may not need us. That is a good outcome. If the answer is another form and another dose, you have learned something about the care you are paying for.
Who this is not for
GoodLife Health is not for someone who wants the next dose and nothing more. If you want a prescription without blood work, a $99 app is built for that. We test first. We take nothing on the medication either way.
It is not for anyone who wants compounded tirzepatide, a guaranteed number on the scale or a promise that insurance will pay. It is for residents of the United States only. It does not replace insurance, so it is not for someone who would drop catastrophic coverage to afford it. Urgent symptoms belong with emergency services.
For everyone else, the offer is simple. The membership is $299 a month. A hold of $598 covers the first two months and is charged only once a clinician accepts you. If you are not accepted, the hold is released and you are never charged. Once you are accepted, those two months are non-refundable. After them, it is month to month. It buys a cardiometabolic panel every quarter, the clinician who stays and medication prescribed to your pharmacy at that pharmacy's price, with nothing taken on it. It returns the diagnosis a visit never produced, your markers followed over time and no repeat of the eight-minute visit. It is different because it tests first, treats second and sells neither the drug nor the dose. If your next dose increase is already scheduled, this is the week to find out why the last one stopped working.
Related Reading
- What a Direct Primary Care Visit Actually Looks Like (2026)
- What Does a Direct Primary Care Membership Include in 2026
References
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss